Investor Relations

IR Home

Stock Chart
VNDA (Common)
ExchangeNASDAQ (US Dollar)
Price$14.25
Change (%) Stock is Down 0.2 (1.38%)
Volume286,956
Data as of 01/18/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
January 2018?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-11234
01/04/18
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
56
78
01/08/18
8-K
Formats:  Excel HTML Adobe PDF Word
910111213
14151617181920
21222324252627
28293031515253

Primary IR Contact

For members of the press or investor community who wish to obtain more information about Vanda, please contact
Jim Kelly
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals, Inc.
(202) 734-3428

Recent News
01/07/18
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance
11/13/17
Vanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
11/10/17
Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Latest Presentation
Download Documentation 2018 Corporate Presentation
Download Documentation Tradipitant Improves Worst Itch and Disease Severity in Patients with Chronic Pruritus Related to Atopic Dermatitis, 9th World Congress of Itch, October 16, 2017

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
  
Home | About Vanda | Product Pipeline| Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2017 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy